{"id":"W2915296465","doi":"10.3747/co.26.4809","title":"Brigatinib is another treatment option for patients diagnosed with advanced ALK-positive non-small-cell lung cancer who are treatment-naïve or who have progressed on or are intolerant to crizotinib","year":2019,"lang":"en","type":"letter","venue":"Current Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; William Osler Health System; BC Cancer Foundation; Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Crizotinib; Medicine; Lung cancer; Internal medicine; Oncology; ALK inhibitor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002807048,0.000204985,0.0003634634,0.0005452571,0.0004329496,0.0009058115,0.0002933972,0.000732047,0.1203292],"category_scores_gemma":[0.0009669214,0.0001385376,0.0005113342,0.0003594333,0.000192022,0.000679329,0.0003481532,0.00145331,0.03313855],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003096325,"about_ca_system_score_gemma":0.0004263517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006267351,"about_ca_topic_score_gemma":0.003576209,"domain_scores_codex":[0.9998577,0.00002227962,0.00001151525,0.00001881628,0.00005696516,0.00003264696],"domain_scores_gemma":[0.9996767,0.00006662572,0.00006158347,0.00001076402,0.0000366217,0.0001477068],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001428985,0.0001951533,0.00190675,0.0004194035,0.00004257699,0.0008051145,0.00005311374,0.00006195837,0.003275615,0.001087294,0.7052277,0.2854963],"study_design_scores_gemma":[0.0005015598,0.0006898296,0.007971458,0.0005121775,0.00008928878,0.002703926,0.00008977982,0.0001441934,0.001588485,0.0008152518,0.9848696,0.00002439793],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"commentary","genre_scores_codex":[0.04451202,0.152983,0.002609021,0.1076012,0.01667055,0.0004167521,0.007313049,0.002467852,0.6654266],"genre_scores_gemma":[0.2971568,0.1409265,0.005583242,0.05445034,0.01061874,0.0003417592,0.007528825,0.0005010528,0.4828928],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.1203292,"threshold_uncertainty_score":0.4025413,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05450463231190626,"score_gpt":0.412521131429233,"score_spread":0.3580164991173267,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}